ESMO 2025 | The future of neoadjuvant therapy for unresectable stage III melanoma
Minke Lucas, MD, Netherlands Cancer Institute, Amsterdam, Netherlands, highlights the potential of neoadjuvant treatment as a new standard of care for resectable stage III melanoma, citing the SWOG S1801 (NCT03698019) and NADINA (NCT04949113) trials as key evidence. While FDA and EMA approvals are pending, several countries are already reimbursing and incorporating these treatments into guidelines, paving the way for a potential shift towards neoadjuvant treatment as a benchmark for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think we are now in a position that we really have to consider neoadjuvant as a new standard of care treatment for resectable stage III melanoma with the S1801 trial and with the NADINA trial together. Of course, there’s at the moment not yet FDA or EMA approval for either one, but I know that there are many countries in which these treatments are now available, are being reimbursed, and are in some cases also applied in the guidelines...
I think we are now in a position that we really have to consider neoadjuvant as a new standard of care treatment for resectable stage III melanoma with the S1801 trial and with the NADINA trial together. Of course, there’s at the moment not yet FDA or EMA approval for either one, but I know that there are many countries in which these treatments are now available, are being reimbursed, and are in some cases also applied in the guidelines. So I think we are getting there. And hopefully in the next few years, we will see really a shift towards this being not only one of the standard of treatments, but maybe the new benchmark treatments in resectable stage III melanoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
